Holen Sie sich die Stockscreener-App
154.98
2.09%
3.17
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$151.81
Offen:
$151.89
24-Stunden-Volumen:
6.78M
Relative Volume:
0.93
Marktkapitalisierung:
$192.33B
Einnahmen:
$29.42B
Nettoeinkommen (Verlust:
$8.51B
KGV:
22.86
EPS:
6.7801
Netto-Cashflow:
$10.02B
1W Leistung:
+1.63%
1M Leistung:
+27.28%
6M Leistung:
+29.00%
1J Leistung:
+46.26%
1-Tages-Spanne:
$151.46
$156.95
1-Wochen-Bereich:
$147.07
$157.29
52-Wochen-Spanne:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
154.98 | 188.40B | 29.42B | 8.51B | 10.02B | 6.7801 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026? - The Globe and Mail
BofA Raises PT on Gilead Sciences (GILD) to $162 From $154Here's Why - Bitget
BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why - Insider Monkey
Focus on These 5 Stocks That Recently Hiked Dividends - TradingView
Gilead Sciences Inc (NASDAQ:GILD) Offers a Sustainable Dividend Backed by Strong Fundamentals - ChartMill
Longbow Finance SA Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - MarketBeat
TD Cowen Raises Gilead Sciences (NASDAQ:GILD) Price Target to $160.00 - MarketBeat
Varma Mutual Pension Insurance Co Has $22.71 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
ING Groep NV Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
LSV Asset Management Has $477.26 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Leuthold Group LLC Takes $4.73 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock price target raised to $170 from $155 at Wolfe Research - Investing.com
Illinois Municipal Retirement Fund Buys 10,657 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Caisse Des Depots ET Consignations Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Gilead Sciences: Scotiabank Maintains Outperform, PT $177 Feb 2026 - Meyka
Gilead Sciences (GILD) Net Margin Reset Challenges Slower Growth Narratives In FY 2025 Results - Sahm
Xilio Therapeutics Announces Pricing of Underwritten Offering - GlobeNewswire Inc.
Gilead Sciences Stock Spikes After Q4 Results: Time to Buy? - Yahoo Finance
Gilead Sciences Earnings Call: HIV Strength, New Catalysts - TipRanks
Gilead Accuses Cipla of Sidestepping Earlier Descovy Patent Deal - Bloomberg Law News
Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case - Yahoo Finance
Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Dividend Increase$0.82 Per Share - MarketBeat
Key facts: Gilead Q4 profit hits $2.18B; signs MoU with UAE Health - TradingView
Morgan Stanley Sees Gilead Gaining Ground In HIV And Oncology - Finimize
TD Cowen Adjusts Gilead Sciences Price Target to $160 From $145, Maintains Buy Rating - marketscreener.com
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Buy Rating on Gilead: Solid Core Growth, Conservative Guidance, and Late-Stage Pipeline Upside Into 2026 - TipRanks
Gilead Sciences Poised for Yeztugo Execution, Pipeline Upside in 2026, Morgan Stanley Says - marketscreener.com
‘Pieces are coming together’ amid Gilead's Yeztugo launch: exec - Fierce Pharma
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales - Finviz
GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus
Gilead's Long HIV Patent Life and Emerging Oncology Portfolio Support a Wide Moat - Morningstar
Oppenheimer Adjusts PT on Gilead Sciences to $165 From $128, Maintains Outperform Rating - marketscreener.com
Truist Securities raises Gilead Sciences stock price target to $152 - Investing.com India
Gilead Sciences (NASDAQ:GILD) Hits New 1-Year High on Earnings Beat - MarketBeat
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes - Schaeffer's Investment Research
Bernstein raises Gilead Sciences stock price target to $160 on growth outlook - Investing.com
Gilead Sciences stock holds steady as Goldman Sachs maintains Neutral rating - Investing.com
Gilead Sciences stock holds steady as Goldman Sachs maintains Neutral rating By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at $153.32 By Investing.com - Investing.com India
Gilead Sciences stock hits all-time high at $153.32 - Investing.com
Gilead Sciences stock price target raised to $160 from $150 at BMO Capital - Investing.com
Gilead Sciences stock price target raised to $160 from $150 at BMO Capital By Investing.com - Investing.com India
Morgan Stanley Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
GILD: Scotiabank Raises Gilead Sciences Price Target Amidst Sect - GuruFocus
Gilead Sciences stock price target raised to $162 from $154 at BofA - Investing.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):